During a recent meeting of the US Senate Committee on Finance, significant concerns were raised regarding the President's 2026 Health Care Agenda, particularly around vaccine policies and pharmaceutical pricing. Senator Cassidy highlighted troubling developments since the President's confirmation, including the dismissal of all 17 members of the Vaccine Advisory Board and the cancellation of $500 million in vaccine research funding.

Senator Cassidy expressed alarm over the administration's approach to oversight, emphasizing the need for Congress to fulfill its constitutional responsibilities as a check on executive power. He pointed out that the current trajectory could lead to a deteriorating health care system and a growing deficit, undermining public trust in government.

The discussion also touched on the contentious relationship between the government and pharmaceutical companies. Senator Cortez Masto introduced legislation aimed at reversing a $5 billion subsidy to big pharma, urging colleagues to support measures that would restore price negotiation power and lower drug costs, which are currently among the highest in the world.

As the committee continues to navigate these complex issues, the implications of their decisions will be crucial for the future of health care in the United States. The call for action reflects a growing urgency to address both vaccine policy and pharmaceutical pricing, with potential impacts on public health and economic stability.